Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO Breast 2024 | PREcoopERA: giredestrant versus anastrozole in ER+/HER2- early breast cancer

Elisabetta Munzone, MD, Istituto Europeo di Oncologia, Milan, Italy, provides an overview of the Phase III, window-of-opportunity (WOO) PREcoopERA trial (NCT05896566), which aims to assess giredestrant, an oral selective ER degraders (SERD), with or without LHRH agonist versus anastrozole in premenopausal women with ER+/HER2- early breast cancer. The primary endpoint is change in Ki-67 labeling index between pre-treatment diagnostic tumor biopsy and post-treatment rebiopsy. This interview took place at the 2024 European Society for Medical Oncology (ESMO) Breast Cancer Annual Congress in Berlin, Germany.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.